Articles tagged "Rejection"

2019 American Transplant Congress
Decreased Rejection and Higher Graft Survival in Pediatric Deceased Donors
P. Budhiraja¹, D. Rotich², J. Mahnken², A. Ilahe¹, A. Naik³, D. Cibrik¹
¹Nephrology, University of Kansas Medical Center, Kansas City, KS, ²Statistics, University of Kansas, Kansas City, KS, ³Nephrology, University of Michigan, Ann Arbor, MI
*Purpose:Pediatric donor kidneys are important pool of donor kidneys which despite the early surgical complications have good long-term graft survival.1 We hypothesize that this survival…
2019 American Transplant Congress
Impact of the 2013 Change in Definition of Increased Risk Donors on Lung Transplant Outcomes
C. J. Lehr¹, R. Lopez², S. Arrigain², J. D. Schold², M. Valapour¹
¹Respiratory Institute, Cleveland Clinic, Cleveland, OH, ²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
*Purpose: The definition for donors at “increased risk” for human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) was updated in 2013 from…
2019 American Transplant Congress
Outcomes Of Treatment Of Late Vs Early Acute Antibody-mediated Rejection In Renal Transplant Recipients – A Single Center Experience
R. Prashar, N. Sulejmani, A. Patel
Henry Ford Transplant Institute, Detroit, MI
*Purpose: The diagnostic accuracy and treatment options for acute antibody-mediated rejection (aABMR) in RTRs has improved over the last several years. However,response to treatment in…
2019 American Transplant Congress
The Impact of Acute Rejection in Heart Transplantation on Post-Transplant Malignancy
K. Kamrani¹, A. Okoh², D. Hanos¹, M. Camacho¹, M. Zucker², K. Clarke¹
¹Dept. of Surgery, Newark Beth Israel Medical Center, Newark, NJ, ²Dept. of Medicine, Newark Beth Israel Medical Center, Newark, NJ
*Purpose: Compared with the general population, an increased incidence of skin cancers and lymphomas have been shown in orthotopic heart transplant (OHT) recipients. However, the…
2019 American Transplant Congress
Long-Term Outcomes of Eculizumab-Treated Positive Crossmatch Recipients: Allograft Survival, Histologic Findings, and Natural History of the Donor-Specific Antibodies
C. Schinstock, A. Bentall, S. Byron, L. Cornell, M. Everly, M. Gandhi, M. Stegall
Mayo Clinic, Rochester, MN
*Purpose: We aimed to determine long-term outcomes for eculizumab-treated, positive crossmatch (+XM) kidney transplant recipients as compared with +XM and age-matched negative crossmatch (−XM) control…
2019 American Transplant Congress
Inhibition of mTORC2 Causes Hyper Phosphorylation of ERK Induced by Co-Ligation of HLA-I and II Antibody
Y. Jin¹, J. Sinnet-Smith², E. Rozengurt², E. F. Reed¹
¹Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA, ²Medicine, University of California Los Angeles, Los Angeles, CA
*Purpose: Transplant recipients developing donor specific antibodies (DSA) are at risk for antibody-mediated rejection (AMR). It has been reported that as many as 30% of…
2019 American Transplant Congress
Elevated Donor Derived Cell Free DNA (dd-cfDNA) Levels in the Presence of Donor Specific Antibodies (DSA) Are a Strong Predictor of Antibody Mediated Rejection (ABMR) in Pediatric Renal Transplant Recipients
D. Puliyanda¹, R. D. Swinford², H. Pizzo¹, J. Garrison¹, I. Kim¹, A. M. De Golovine², S. Jordan¹
¹Pediatric Nephrology, Cedars-Sinai Med Ctr, Los Angeles, CA, ²Pediatric Nephrology, UTHealth, Houston, TX
*Purpose: A renal biopsy, the gold standard for the diagnosis of antibody mediated rejection (ABMR) in transplant recipients, is invasive and may be associated with…
2019 American Transplant Congress
Urinary Cell mRNA Sequencing Profiles of Kidney Allograft Recipients Mirror Intragraft Events and Demonstrate Enrichment for Immune Cells
M. Lubetzky¹, A. Verma², H. Yang¹, T. Muthukumar¹, S. Salvatore¹, J. Lee¹, D. Dadhania¹, S. Seshan¹, F. Mueller¹, O. Elemento², M. Suthanthiran¹
¹Division of Nephrology, Weill Cornell, New York, NY, ²Institute for Computational Biomedicine, Weill Cornell, New York, NY
*Purpose: Urinary cell mRNA profiling to interrogate kidney allograft status is based on the premise that the allograft can function as an in-vivo flow cytometer…
2019 American Transplant Congress
Three-Year Outcomes of Highly-Sensitized Kidney Transplant Recipients Desensitized with Imlifidase (IdeS)
E. Huang¹, J. Choi¹, A. Vo¹, A. Peng¹, R. Najjar¹, S. Sethi¹, C. Kjellman², L. Winstedt², N. Ammerman¹, S. C. Jordan¹
¹Cedars Sinai Medical Center, Los Angeles, CA, ²Hansa Medical, Lund, Sweden
*Purpose: The HLA-incompatible (HLAi) barrier has been traversed using desensitization therapies with IVIg, rituximab and/or plasmapheresis, although antibody-mediated rejection (ABMR) continues to be observed in…
2019 American Transplant Congress
APRIL^-/-/BLyS^-/-Deplete Antibody Secreting Cells and Alloantibody Production in Sensitized Antibody Mediated Rejection Model
N. Bath, B. Verhoven, N. Wilson, R. Redfield III
University of Wisconsin, Madison, WI
*Purpose: Antibody mediated rejection (AMR) is a major cause of kidney allograft failure. APRIL (A proliferation inducing ligand) and BLyS (B Lymphocyte Stimulator) are two…